Follow us on social media
Home / Biohacking Academy / Metabolic
MetabolicEvidence: Clinical (Phase 2)

Retatrutide and the triple-agonist era of metabolic research

From GLP-1 to GIP to glucagon: how one engineered peptide came to engage three hormone receptors, and what the first clinical data actually showed.

Listen to this articleAudio version
0:00 / 3:21
In this article
Key takeaways
  • Retatrutide is a single peptide that activates GIP, GLP-1 and glucagon receptors.
  • Adding glucagon-receptor activity is designed to raise energy expenditure and hepatic fat oxidation.
  • Phase 2 data reported a mean body-weight reduction of up to 24.2% at 48 weeks; phase 3 studies are ongoing.

Metabolic peptide research has moved in clear generations. First came selective GLP-1 receptor agonists. Then dual GIP/GLP-1 agonists. Retatrutide (LY3437943) represents the third step: a single molecule that engages three receptors at once.

3Receptors engaged: GIP, GLP-1, glucagon
~6 daysReported half-life in early studies
24.2%Mean weight reduction at 48 weeks, highest-dose arm (Phase 2)

Three generations of incretin research

CompoundReceptorsResearch focus
SemaglutideGLP-1Appetite, gastric emptying, glycemic control
TirzepatideGIP + GLP-1Dual incretin signaling
MazdutideGLP-1 + glucagonEnergy expenditure, visceral fat
RetatrutideGIP + GLP-1 + glucagonCombined appetite, glycemic and energy-expenditure effects

Why add glucagon?

Glucagon is best known for raising blood glucose, which makes it an unexpected partner in metabolic research. But glucagon-receptor signaling also increases energy expenditure and promotes fatty-acid oxidation in the liver. Pairing it with GLP-1 and GIP activity, which counter its glycemic effect, is the rationale behind tri-agonism .

How the molecule is built

Retatrutide is based on a GIP peptide backbone, modified to also activate GLP-1 and glucagon receptors, and conjugated to a fatty diacid moiety that binds albumin in circulation. That albumin binding slows clearance and underlies a reported half-life of about six days in early pharmacology studies .

What the clinical data showed

In a 48-week phase 2 trial in adults with obesity, published in the New England Journal of Medicine, retatrutide produced dose-dependent reductions in body weight, reaching a mean of 24.2% in the highest-dose group versus 2.1% with placebo . A separate phase 2 trial in type 2 diabetes reported meaningful reductions in HbA1c and body weight . In a substudy focused on liver fat, a majority of participants in the higher-dose groups reached liver-fat levels within the normal range by 48 weeks .

Tri-agonism does not just add a third pathway. It changes the balance between eating less and spending more.

Safety signals observed

As with other incretin-based compounds, the most frequent adverse events in trials were gastrointestinal (nausea, diarrhea, vomiting), largely mild to moderate and more common during dose escalation. Dose-related increases in heart rate were also reported . These observations come from controlled clinical settings with medical supervision.

What remains open

  • How much of the weight lost is fat mass versus lean mass, and how that compares across agonist classes.
  • Durability of effects and what happens after treatment stops.
  • Long-term cardiovascular and hepatic outcomes, which the phase 3 TRIUMPH program is designed to evaluate.

References

  1. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234–1247.
  2. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514–526.
  3. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529–544.
  4. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30:2037–2048.

This article is for educational and research purposes only. Peptogen products are research-grade compounds intended exclusively for laboratory and in-vitro research. They are not for human or animal consumption, diagnostic or therapeutic use, and nothing here constitutes medical advice or dosing guidance.

Retatrutide 20 mg vial
Related research compound

Retatrutide 20 mg

$240 USD